47 results on '"Califano, R."'
Search Results
2. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
3. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
4. Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
5. First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
6. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
7. The effect of human-mattress interface's temperature on perceived thermal comfort
8. 82P The role of circadian rhythms in NSCLC immunotherapy efficacy: A focus on first dose timing
9. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)
10. LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2
11. 66P Real-world data of first-line chemo-immunotherapy for patients with extensive stage SCLC: A multicentre experience from Switzerland and the UK
12. Prise en charge du cancer bronchique à petites cellules (CPC) (localisé et étendu)
13. LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
14. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
15. 33P Real-world experience of MET TKI-induced peripheral edema
16. PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L
17. LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
18. 1541P Real-world data of atezolizumab plus carboplatin-etoposide for patients with extensive stage SCLC: The UK experience
19. Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013
20. 1195P Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L
21. PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial
22. PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
23. OFP01.03 Systemic and Intracranial Efficacy of Brigatinib vs.Crizotinib: Updated Results from the ALTA-1L Trial
24. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
25. LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
26. 1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial
27. 1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L
28. 108P Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes
29. LBA1 - Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
30. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration
31. 1736O - IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
32. 49O - IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
33. LBA58 - Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
34. 1462P - Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts)
35. P2.13-01 Brigatinib Use in England – Where Next?
36. MA 10.07 Elderly Lung Cancer Patients on Immunotherapy: Preliminary Results from the ELDERS Study
37. 1303PD - Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status
38. 1269P - SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting
39. List of Contributors
40. 1081O_PR - Professional Burnout in European Young Oncologists: a European Survey Conducted By the European Society for Medical Oncology (Esmo) Young Oncologists Committee
41. 1282P - Brain Metastases (Bm) in Patients with Egfr Mutations – a Review of Incidence and Outcomes
42. 1260P - Outcomes of Elderly Patients (≥70 Yo) with Advanced Non-Small Cell Lung Cancer (Nsclc): a Multi-Institutional Analysis
43. 1242P - A Phase I Study of the Mek1/2 Inhibitor Selumetinib in Combination with First-Line Chemotherapy Regimens for Nsclc
44. 1194P - Incomplete (R1) Resection for Early Stage Non Small Cell Lung Cancer (Nsclc): a Single Institution Experience from the University Hospital of South Manchester (Uhsm)
45. Smoking in teenagers
46. A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC)
47. 148PD OUTCOMES OF SMALL CELL LUNG CANCER (SCLC) PATIENTS TREATED WITH SECOND-LINE CHEMOTHERAPY (SL): A RETROSPECTIVE ANALYSIS OF 166 PATIENTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.